Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Explore this paper's citation graph
Summary
The authors’ full names, academic de‐ grees, and affiliations are listed in the Ap‐ pendix.
- Type
- letter
- Published
- 2015-09-24
- Cited by
- 4,221
- References
- 5
- OpenAlex
- https://openalex.org/W2344221521
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4905508
Keywords
Medicine, Ipilimumab, Nivolumab, Melanoma, Oncology
References
- High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
- A novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent very late stent thrombosis.
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Long-term use of ticagrelor in patients with prior myocardial infarction.
- Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma
Cited by
- CTLA-4 and PD-1 Pathways
- Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
- Treatment of melanoma brain metastases
- Cancer treatment and survivorship statistics, 2016
- Therapie des metastasierten malignen Melanoms
- The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
- Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
- PD-1 and its ligands are important immune checkpoints in cancer
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- How co-stimulatory and co-inhibitory pathways shape atherosclerosis
- “Targeted” Chemotherapy for Esophageal Cancer
- Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- From Famine to Feast: Developing Early Phase Combination Immunotherapy Trials Wisely
- Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
- Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy
- Cancer immunology and melanoma immunotherapy
- B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
- Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
Related papers
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
- Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients.
- Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
- Figure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
- Blockade of Programmed Cell Death Protein-1 Pathway For the Treatment of Melanoma
- 266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939
- Immunotherapy of Melanoma: Facts and Hopes
- 577 Circulating tumor DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients